Capricor Therapeutics Inc
NASDAQ:CAPR

Watchlist Manager
Capricor Therapeutics Inc Logo
Capricor Therapeutics Inc
NASDAQ:CAPR
Watchlist
Price: 6.79 USD -3.82% Market Closed
Market Cap: 310.4m USD

Net Margin
Capricor Therapeutics Inc

-317.1%
Current
-1 245%
Average
-6.4%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-317.1%
=
Net Income
-55.1m
/
Revenue
17.4m

Net Margin Across Competitors

Capricor Therapeutics Inc
Glance View

Capricor Therapeutics, Inc. engages in the discovery, development and commercialization of first-in-class biological therapies for the treatment of cardiac and other serious medical conditions. The company is headquartered in Beverly Hills, California and currently employs 48 full-time employees. The company went IPO on 2002-06-04. The firm consists of cell therapy program, including CAP-1002 for Duchenne Muscular Dystrophy program and CAP-1002 with CAP-1002 for coronavirus (COVID-19). The Company’s lead candidate, CAP-1002, is an allogeneic cardiac-derived cell therapy. CAP-1002 is in clinical development for treating Duchenne muscular dystrophy and the cytokine storm associated with COVID-19. Capricor is also developing its exosome technology therapeutic platform. The firm is focused on developing exosomes capable of delivering nucleic acids, including messenger RNA (mRNA) as well as proteins, to treat or prevent a range of diseases. CAP-1002 cell therapy programs initiated Pivotal Phase III, HOPE-3.

CAPR Intrinsic Value
33.38 USD
Undervaluation 80%
Intrinsic Value
Price
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-317.1%
=
Net Income
-55.1m
/
Revenue
17.4m
What is the Net Margin of Capricor Therapeutics Inc?

Based on Capricor Therapeutics Inc's most recent financial statements, the company has Net Margin of -317.1%.

Back to Top